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RET proto-oncogeneAbstract Background: Multiple endocrine neoplasia type 2A (MEN2A) is a rare cancer
associated-syndrome, inherited in an autosomal dominant fashion and caused by germline mutation
in RET proto-oncogene. Clinical diagnosis depends on the manifestation of two or more certain
endocrine tumors in an individual, such as medullary thyroid carcinoma, pheochromocytoma,
and parathyroid adenoma or hyperplasia. Prophylactic total thyroidectomy with central neck
lymph node dissection is mandatory for mutation carriers, with periodic monitoring of the other
concerned organs.
Subjects and methods: We have screened 27 individuals from a large Arab family with multiple
affected members. Mutational screening involved the hotspot regions in the most commonly
implicated exons 10 and 11 of RET proto-oncogene using PCR amplification of the coding and
the flanking intronic regions followed by the Sanger sequencing. We aimed for confirmation of
the clinical diagnosis and identification of at-risk asymptomatic mutation carriers.
Results: A pathogenic variant c.1901G> T (p.Cys634Phe), in exon 11 of RET proto-oncogene
was identified in 15 members of different ages.
Conclusion: Genetic counseling plays a key role in the management of such high-risk families
and hence helps in avoiding or reducing disease recurrence in their future generations.
 2016 Ain Shams University. Production and hosting by Elsevier B.V. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Multiple endocrine neoplasia type 2 (MEN2) is a rare cancer
associated-syndrome, inherited in an autosomal dominant
fashion and caused by germline mutation in RET proto-
oncogene. The main manifestation is medullary thyroidEN type
2 M. Marafie et al.carcinoma (MTC), which is a cancer of the parafollicular C/or
calcitonin secreting cells. It is classified into three subtypes:
MEN2A, familial medullary thyroid cancer (FMTC) and
MEN2B. In FMTC, MTC is the only presented phenotype
and it occurs at a later age of onset with a relatively better
prognosis. MEN2B syndrome is characterized by MTC that
occurs in childhood, with an increased risk for pheochromocy-
toma, mucosal neuroma of lips and tongue, ganglioneuroma of
the gastrointestinal tract and Marfanoid habitus [1,2]. In
MEN2A associated-families, individuals with pathogenic
mutations are at increased risk (95%) for development of early
adult onset MTC (multifocal or bilateral), which is often asso-
ciated with C-cell hyperplasia; also risk is increased for
pheochromocytoma (50%) and parathyroid adenoma or
hyperplasia (20–30%) [2,3]. The prevalence of MEN 2A is
estimated to be 1 per 50,000, with usual diagnosis age of
20–30 years. De novo mutations may to be responsible for
around 5% of MEN2A patients [4].
RET proto-oncogene is located on chromosome 10 (10.
q11.2); it comprises 21 exons and encodes a transmembrane
tyrosine kinase receptor protein which plays an important role
in transferring cell growth and differentiation signals. It is
expressed in parafollicular C cells of the thyroid gland,
parathyroid glandes, adrenal medulla and in the urogenital
system [5].
The clinical phenotype depends on type and position of
gene mutation [1,6,7]. All reported mutations; their associated
phenotypes and the pertinent literature references are shown in
the public mutation repository MEN2-RET databases: (http://
www.arup.utah.edu/database/MEN2/MEN2_welcome.php);
2016 [accessed 1.8.16]. To date; 166 variants are stored in this
database. The most frequently reported mutations are at
codons 634 in exon 11, and 620, 618, 611, 609, which are
located in exon 10. However, mutations at codon 634 have
been reported in 85% of tested individuals, nearly 50% of
them are amino acid cysteine to arginine substitution
(Cys634Arg). Pathogenic variants at this codon reported to
result in a higher incidence of pheochromocytoma, hyper-
parathyroidism and lichen amyloidosis [3,4,8]. Additionally,
the risk of development of the Hirschsprung disease in carriers
could reach 7% [9].
Many guidelines have been established for improvement of
the diagnosis and for better management of patients with
MTC or neuroendocrine tumors [10–13]. Based on the aggres-
siveness of thyroid tumors and the age of clinical detection, the
revised guidelines by American Thyroid Association (ATA)
Task Force on Medullary Thyroid Carcinoma has classified
RET variants at codon C634 (C634F/G/R/S/W/Y) as high risk
mutations (category H) [12]. In general, the recommendations
included periodic assessment of the clinical status by thyroid
ultrasound and biochemical screening for MTC, CT and
MRI for pheochromocytoma, with serum calcium and
parathyroid hormone level assessment [10–13].
MTC is the most common cause of death in MEN2-
associated families. Therefore prophylactic total thyroidec-
tomy with central neck lymph node dissection is mandatory
for RET mutation carriers, with periodic monitoring for resid-
ual or recurrent MTC and annual calcium calcitonin stimula-
tion test. Prophylactic surgery is recommended for young
individuals of <5 years of age, who are carriers for certain
high-risk pathogenic variants in codon 634 [12,13], whilePlease cite this article in press as: Marafie M et al., A germline RET proto-oncogene m
2A-associated clinical manifestations, Egypt J Med Hum Genet (2016), http://dx.dobiochemical screening for pheochromocytoma and hyper-
parathyroidism should start at 8 years of age [12].
We have screened the first Kuwaiti family with multiple
affected members, for confirmation of the clinical diagnosis
and as a measure for identification of at-risk asymptomatic
mutation carriers.
2. Subjects and methods
2.1. Family data
The proband (P9) was 35 year old healthy male, approached
the cancer genetics clinic seeking genetics counseling and pre-
dictive gene testing. Pedigree analysis and medical reports
revealed many relatives manifesting thyroid/parathyroid/adre-
nal associated-diseases consistent with the diagnosis of
MEN2A syndrome (Fig. 1, Table 1). Subsequently his high-
risk family members (P1–P27) were seen in groups or in sepa-
rate individualized sessions according to their request. Genetic
counseling was provided, the importance of predictive gene
test was discussed, and informed consent was obtained for
blood collection and testing. The work has been carried out
in accordance with The International Code of Medical Ethics
of the World Medical Association (Declaration of Helsinki)
and Ethical approval of the Kuwait Medical Genetics Center.
2.2. Molecular screening
Blood samples were obtained from 27 individuals in the fam-
ily. Genomic DNA was extracted from peripheral blood leuko-
cytes using the automatic Maxwell 16 System DNA
purification Kits (Promega, USA) according to manufacturer’s
protocol. We initially performed mutational screening for the
hotspot regions in the most commonly implicated exons 10
and 11 of RET proto-oncogene using PCR amplification of
the coding and the flanking intronic regions, followed by the
Sanger sequencing of the PCR product using ABI PRISM
3100 Genetic Analyzer (Applied Biosystem, USA). We used
the previously designed primers and conditions for amplifica-
tion of exons 10 and 11 [14]. We did not proceed to test other
exons; soon the pathogenic variant was identified.
3. Result and discussion
We have identified a heterozygous variant in exon 11 of RET
proto-oncogene; c.1901G > T; p.Cys634Phe (or C634F as
commonly used in the literature) (Fig. 2); in the proband
and 14 members of his family. Mulligan et al. had previously
described this variant in 1993 as a disease causing mutation
[15]. It was later published as pathogenic mutation by Gene
Review, PMID:20301434 (http://www.ncbi.nlm.nih.gov/
books/NBK1257), and was reported in ClinVar database, as
NM_020975.4 at (http://www.ncbi.nlm.nih.gov/clinvar); 2016
[accessed 1.8.2016]. This is a missense mutation that occurred
at the cysteine residue within the extracellular cysteine-rich
domain. It substitutes cysteine for phenylalanine. This is a hot-
spot gene position for pathogenic mutations, which are com-
monly found in various populations and ethnic groups
including North Africans, but with different frequencies due
to different genetic background [3,4,16–20]. Codon 634utation in multiple members of an Arab family with variable onset of MEN type
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Figure 1 Family pedigree. The proband (P9) is indicated with an arrow. (P1–P27) represent family members that were tested, open
symbols for non-symptomatic individuals; diagonal bars for deceased members. Symptomatic individuals are indicated with solid symbols.
j An affected male. d An affected female.
Table 1 Clinical characteristics of adult heterozygous carriers with RET c.1901G > T; (p.Cys634Phe) pathogenic variant in a
MEN2A family.
P Age 1
(years)
Age 2
(years)
Sex Manifestation Intervention
P3 72 70 F MTC, Parath, Pheo Thyroidectomy, parathyroidectomy, Rt adrenalectomy
P5 70 54 F MTC, Parath, Pheo Thyroidectomy, parathyroidectomy, Rt adrenalectomy
P7 46 46 F MTC, Lichen cutaneous amyloidosis Planned for thyroidectomy
P8 44 44 M Pheo, Planned for thyroidectomy, adrenalectomy
P9* 35 – M No UCI
P10 47 45 F MTC, Parath Thyroidectomy, parathyroidectomy
P11 45 30 F C-cell hyperplasia Prophylactic thyroidectomy
P12 47 – M No UCI
P13 30 16 F C-cell hyperplasia Prophylactic thyroidectomy
MTC: medullary thyroid carcinoma, Parath: parathyroid hyperplasia/or adenoma, Pheo: pheochromocytoma. M: male, F: female,
P = patient’s number as in Fig. 1, P9* = proband, Age 1 = age at molecular test, Age 2 = age at first clinical manifestation, UCI = under
clinical investigation.
Germline RET proto-oncogene mutation in multiple members 3mutation was the most commonly detected missense mutation
in many studies (55–93%); Cys634Arg being the most preva-
lent mutation followed by Cys634Tyr and CYs634Gly
[3,7,19,20], whereas our family variant Cys634Phe was less
commonly reported [14]. However; it has been detected in
2/15 French patients with pheochromocytoma [21], and out
of the 31 screened MTC-associated Moroccan patients, only
one carried this mutation; he developed MTC and pheochro-
mocytoma at the age of 34 years [22].
In this family seven out of 15 heterozygous carriers had
developed clinical manifestations (Fig. 1, Table 1). Among
the affected members; we observed intra-familial variability
in phenotypes and disease onset, with an average age at onset
of 43.6 years; the youngest case was a 16 year old female (P13),
while the oldest case was a 70 year old woman (P3). Moreover,
two sisters P3 and P5 had developed the full disease spectrumPlease cite this article in press as: Marafie M et al., A germline RET proto-oncogene m
2A-associated clinical manifestations, Egypt J Med Hum Genet (2016), http://dx.doat a later age; having MTC with no local or distal metastasis,
parathyroid adenoma and unilateral pheochromocytoma, both
had no clinical complaint until the clinical diagnosis ages,
which were 70 and 54 years respectively. In P3 patient,
pheochromocytoma was the first symptom of MEN2A, caus-
ing sudden severe high blood pressure crises that required
immediate hospitalization. Their mother died at an old age
long time ago due to thyroid cancer as was claimed by her rel-
atives. Another relative (P10), the daughter of (P3), was diag-
nosed with MTC and parathyroid adenoma at the age of
47 years with no nodal metastasis. Very recently; her 46 year
old sister (P7) was diagnosed with MTC and the only member
with cutaneous lichen amyloidosis; her 44 year old brother
(P8) had sudden severe hypertensive crises, due to pheochro-
mocytoma of left adrenal gland. P11 who is the husband of
P10 and her first cousin, was symptomatic and proved to beutation in multiple members of an Arab family with variable onset of MEN type
i.org/10.1016/j.ejmhg.2016.08.006
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Figure 2 Partial DNA sequence for exon 11 of RET proto-oncogene, showing (A) c.1901G > T heterozygous variant found in the
proband (arrow), (B) normal control DNA sequence of RET gene showing the wild type at same position (arrow).
4 M. Marafie et al.a heterozygous carrier. However; three of their children (P22,
P23, and P25; aged 16, 12 and 5 years) proved to be asymp-
tomatic heterozygous carriers. One of the carriers (P25) was
a 5 year old girl with Down syndrome, who is currently asymp-
tomatic. Additionally, the proband (P9) and four more rela-
tives were asymptomatic; being an adult (P12) and three
other children (P20, P26 and P27) who were below 16 years
of age. All were referred to the endocrine clinic for further clin-
ical management.
Distant metastasis was significantly associated with C634R
mutations than with C634Y or C634W mutations, while
individuals harboring C634R, seem to have more aggressivePlease cite this article in press as: Marafie M et al., A germline RET proto-oncogene m
2A-associated clinical manifestations, Egypt J Med Hum Genet (2016), http://dx.dodisease, as demonstrated by more frequent distal metastasis
at diagnosis and at an earlier ages according to the Kaplan–
Meier estimate of cumulative lymph node and distant metas-
tases rates [23]. In contrast, the C634Y genotype appears to
have an indolent behavior [7,23]. In the current family, it seems
that variant c.1901G > T (p.Cys634Phe)/or (C634F) is of low
aggressive effect or of slow-growing phenotype in comparison
to other reported point mutations at this codon. This is
because most of the affected members were diagnosed after
the age of 40 years (5/7), and 2/7 had underwent prophylactic
thyroidectomy at the ages of 16 and 30 due to c-cell hyperpla-
sia. Also all the thyroid tumors in the affected members wereutation in multiple members of an Arab family with variable onset of MEN type
i.org/10.1016/j.ejmhg.2016.08.006
Germline RET proto-oncogene mutation in multiple members 5not associated with local or distal metastasis. In conclusion;
MEN2A is a serious hereditary disease that involves not only
adults, but also young children. Therefore these genetically pre-
disposed families should be educated about the importance of
testing their at-risk members; including children as young as
few months of life in an attempt to detect the disease at an
early age and proceed with preventive surgical intervention
at the proper time.
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